A Phase 2 interventional study of Tramadol and Placebo in Opioid-Induced Bowel Dysfunction and Constipation, sponsored by Asbjørn Mohr Drewes. Completed at 1 site in Denmark. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-26.
Sponsored by Asbjørn Mohr Drewes · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Tramadol is a weak opioid and widely used to treat moderate to severe pain. Stronger opioids are known to inhibit gastrointestinal motility and secretion, however the effects of tramadol on gastrointestinal function remains less understood. The aim of this study was to determine to what degree tramadol causes opioid-induced bowel dysfunction by using an objective design to explore gastrointestinal transit, motility pattern, secretion, and colonic volume, in a group of healthy male volunteers.
87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.
This study's enrollment of 20 is below the median of 119 across 68 interventional studies indexed under Opioid-Induced Constipation.
Browse Opioid-Induced Constipation studies →Asbjørn Mohr Drewes is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tramadol
Drug: Tramadol
Placebo
Drug: Placebo
Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)
Placebo is administered orally twice daily.
Total gastrointestinal transit time
Difference in hours from ingestion of a 3D Transit Capsule to expulsion of the capsule during active and placebo treatment
Time frame: From day 4 to day 8
Colorectal transit time
Difference in hours from the entering in the colon of a 3D Transit Capsule to expulsion of the capsule during active and placebo treatment
Time frame: From day 4 to day 8
Constipation symptoms
Measured on the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire (ranging from 0 (symptom absent) to 4 (very severe).
Time frame: From day 1 to day 10
Bowel movement frequency
Number of spontaneous bowel movements per day
Time frame: From day 1 to day 10
Stool consistency
Rated on the Bristol Stool Form Scale (ranging from type 1 (constipation) - type 7 (diarrhea))
Time frame: From day 1 to day 10
Gastrointestinal symptoms
Measured on the Gastrointestinal Symptom Rating Score (GSRS) questionnaire (ranging from 0 (no discomfort) to 6 (very severe discomfort)
Time frame: Day 1 and day 10
Opioid-induced constipation
Measured by the Bowel Function Index (BFI) questionnaire (ranging from 0 (not at all) to 100 (very strong).
Time frame: Day 1 and day 10
Diagnostic evaluation of opioid-induced constipation
Assessed using the Rome IV C6 criteria consisting of 7 items rated as either true or false. 2 or more items rated as "true" indicates functional constipation
Time frame: Day 10
Colonic motility patterns
Number of motility patterns in the colon measured by the 3D Transit Capsule
Time frame: From day 4 to day 8
Opiate withdrawal symptoms
Measured by the Subjective Opiate Withdrawal Scale (ranging from 0 (not at all) to 4 /extremely)
Time frame: Day 13, 14 or 15
Colon volume
Volumetric quantification of the colon measured using T2-weighted MRI images
Time frame: Day 10
Colonic water content
Analysis of colonic water content measured using heavily T2-weighted MRI images
Time frame: Day 10
Gastric half emptying time
Analysis of gastric half emptying time after ingestion of a standardized meal measured by MRI
Time frame: Day 1 and day 10
Gastric contraction assessment
Analysis of gastric contraction amplitude after ingestion of a standardized meal measured by MRI
Time frame: Day 1 and day 10
Gastric contraction assessment
Analysis of gastric contraction frequency after ingestion of a standardized meal measured by MRI
Time frame: Day 1 and day 10
Small bowel motility assessment
Analysis of small bowel motility after ingestion of a standardized meal measured using dynamic MRI images. A semi-automated analysis software enables registration of small bowel motility with the calculation of regional motility maps and quantification of motility indices.
Time frame: Day 1 and day 10
Small bowel water content
Analysis of small bowel water content measured using heavily T2-weighted MRI images
Time frame: Day 1 and day 10
Plan to share: Yes — Data can be provided upon request
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in May 2023, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tramadol
Asbjørn Mohr Drewes